Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-658-1 | CAS number: 123-86-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
N-butyl acetate is readily absorbed after inhalation exposure or tracheal intubation. Dermal absorption is low. Absorption is followed by rapid systemic distribution throughout the body. Hydrolysis to metabolites n-butanol and acetic acid, a process mediated by esterases, is fast, with half life in blood being less than one minute.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - inhalation (%):
- 100
Additional information
Toxicokinetics
For n-butyl acetate toxicokinetic data are available after intravenous application (Deisinger et al., 1997; Teeguarden et al., 2005) and inhalation/intratracheal intubation (Poet et al., 2002 corresponds to IUCLID study record ESR OPP/ACC,2002; Groth and Freundt, 1991; Essig et al., 1989). Additionally, data on hydrolysis (Dahl et al., 1987; Longland et al., 1977), on tissue/blood partition coefficients (Kaneko et al., 1994), and on skin permeability in vitro (Ursin et al., 1995; Rauma, 2009) were obtained.
The absorption of n-butyl acetate after inhalation exposure or tracheal intubation was investigated in three studies. Investigations with male Sprague Dawley rats using a whole body plethysmograph indicated that n-butyl acetate is readily absorbed after inhalation exposure. The respiratory bioavailability of n-butyl acetate was calculated to be 100% of alveolar ventilation (about 60% of minute ventilation). Maximum blood levels of n-butyl acetate (2.43 +/- 2.7 µg/ml) were reached about 10 minutes after start of exposure to n-butyl acetate (2000 ppm at start of exposure). Except for the first measurement after 5 minutes the n-butanol blood levels (maximum: 8.18 +/- 3.1 µg/ml, 20 minutes after start of exposure) were higher than the n-butyl acetate blood levels (Poet et al., 2002 corresponds to IUCLID study record ESR OPP/ACC,2002; Teeguarden et al., 2005).
Similar results were obtained with female Sprague Dawley rats which were exposed for 5 hours to 1000 ppm n-butyl acetate via tracheal intubation. Both, n-butyl acetate and its metabolite n-butanol were detectable in blood immediately after start of exposure, maximum levels were reached at about 30 minutes after start of exposure. The concentration of n-butyl acetate reached a nearly constant level (mean concentration: 24.6 +/- 3.8 µmol/L). The blood concentrations of n-butanol followed were about twice the levels of n-butyl acetate (mean concentration: 52.4 +/- 10.3 µmol/L; AUC: 260 +/- 29 µmol per Lxh) (Groth and Freundt, 1991).
These findings were supported by another investigation with Sprague Dawley rats, which were exposed for 1 hour to 7000 ppm n-butyl acetate via intratracheal intubation (Essig et al., 1989).
Absorption of n-butyl acetate after dermal application seems to be low as can be concluded from the permeability constant for n-butyl (1.6 +/- 0.1 g/m2*h or 1.8 +/- 0.1 cm3/m2*h), which was obtained in vitro using human skin (Ursin et al., 1995). Similar results were obtained in vitro using pig-skin (flux = 0.47 +/- 0.07 mg/cm2/h; Rauma, 2009). Based on the data on physico-chemical properties on n-butyl acetate a default assumption of 100% dermal absorption can be taken into account following the recommendations of the Guidance on Information Requirements and Chemical Safety Assessment Chapter R.7c (i.e. water soluble liquid with molecular mass below 500 and log Pow in the range of -1 to 4).
n-Butyl acetate is rapidly distributed throughout the body as can be seen from investigations with Sprague Dawley rats, which received radioactive labelled n-butyl acetate intravenously. Liquid scintillation analysis of whole blood and brain tissue of these rats
revealed rapid systemic distribution of radioactivity and very rapid elimination from both whole blood and brain tissue (Deisinger et al., 1997).The metabolism of n-butyl acetate is characterised by the rapid hydrolysis of the parent compound to n-butanol and acetic acid, a process which is catalyzed by esterases found in several tissues and blood (Dahl et al., 1987, Longland et al., 1977). Metabolism studies with male Sprague Dawley rats using radioactive labelled n-butyl acetate indicated that n-butyl acetate was very rapidly eliminated from the blood (biphasic elimination; t1/2 = 0.41 min), and was detected in brain tissue only at low concentrations (mean maximum of 3.8 µg equivalents/g at 1.9 min) in the first 2.5 min following dosing. n-Butanol was found at higher concentrations in both blood (Cmax = 52 µg equivalents/g at Tmax 2.6 min)and brain (Cmax = 79 µg equivalents/g at Tmax 2.5 min), but this was also rapidly eliminated in both tissues (biphasic elimination; t1/2, of 1.0 - 1.2 min) and was undetectable beyond 20 min post dosing. n-Butyric acid was present at low concentrations in blood (mean maximum of 5.7 µg equivalents/g at 7.4 min) and declined slowly following dosing; it was largely undetected in brain tissue. Early eluting, polar metabolites, presumably Krebs cycle intermediates of [14C]n-butanol and glucuronide and sulfate conjugates of [14C]n-butanol, were detected in the whole blood (mean maximum of 12.2 µg equivalents/g at 4.2 min), but were seen only in trace amounts in brain tissue. The hydrolysis of n-butyl acetate in blood and brain is estimated to be 99% complete by 2.7 min at this dose level (Deisinger et al., 1997).
Parameter |
n-Butanol in blood |
n-Butanol in brain |
A |
24.365 |
48.050 |
alpha (min') |
1.890 |
1.574 |
t1/2 alpha(min) |
0.367 |
0.440 |
B |
65.447 |
105.472 |
beta (min') |
0.215 |
0.147 |
t1/2 beta (min) |
3.228 |
4.714 |
Kelim (min-1) |
0.669 |
0.594 |
t1/2 (min) |
1.036 |
1.167 |
Cmax (µg/g) |
52.2 |
79.2 |
Tmax (min) |
2.6 |
2.5 |
The findings from Deisinger et al. (1997) were confirmed in further studies (Teeguarden et al., 2005; Essig et al., 1989).
There were no data on excretion identified. But the data on metabolism revealed that n-butyl acetate is rapidly hydrolyzed to n-butanol and acetate, which are further metabolized and finally enter the Krebs cycle.
The toxicokinetic data of n-butyl acetate obtained in several studies (see above) and information on partition between distilled water, olive oil, human blood and various rat tissues (blood, liver, kidney, brain, muscle, and fat) (Kaneko et al., 1994) were used for the establishing a PBPK-Model for n-butyl acetate and its metabolites (Barton et al., 2000; Teeguarden et al., 2005).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.